Concit Pharma recieves approval to start Phase IIa study

  • Friday, July 12, 2013 at 10:15AM
  • On July 1st Concit Pharma received approval of protocol for the Phase IIa study in L-DOPA induced dyskinesia. The approval is an important milestone and strongly supports Concit Pharma's development plans.

    Concit Pharma presents JM-010 at Sydney meeting

  • Monday, June 10, 2013 at 9:55AM
  • Concit Pharma will present JM-010 at the Movement Disorder Society meeting in Sydney, Australia June 16-20. The preclinical data suppporting the efficacy and safety of JM-010 as a new drug for treatment of L-DOPA induced dyskinesia will be presented on a poster.

  • A copy of the poster can be obtained upon request (kbh@concitpharma.com).

    Concit Pharma and Copenhagen University starts joint project

  • Tuesday, October 2, 2012 at 2:23PM
  • On October 1st Concit Pharma and Neurobiological Research Unit, Copenhagen National Hospital (Rigshospitalet) has initiated a research project supported by The Danish National Advanced Technology Foundation. The project will during the next two years focus on identification and characterization of new drugs for treatment of L-DOPA induced dysinesia.

    Concit Pharma raises new capital

  • Tuesday, June 12, 2012 at 9:24AM
  • Concit Pharma raises new capital and wellcomes Dr. Magnus Persson and Dr. Carsten Schou as new members of the board of directors.

  • Concit Pharma has projects focusing L-DOPA induced dyskinesia and neuropathic pain and the new investment from Novo AS and Seed Capital will make it possible to further progress the projects towards testing in man. It is expected that the clinical studies will be initiated in early 2013.

  • Dr. Magnus Persson, MD has a long experience from pharma and biotech and has during the last 15 years been Partner in two Life Sciences Venture Capital firms, one with its base in Sweden and with global reach and one in The Bay Area in California. Magnus has a long experience in medicine, life sciences and biotech financing. He has led development teams of Phase II and III programs in the Pharmaceutical Industry. He has founded, and led private as well as public biotech and medtech companies as Chairman of the Board and Board Director in the Nordic Countries, Europe and USA. Magnus will be independent membe rof the board.

  • Dr Carsten Schou will represent Seed Capital and therefore replaces Frank Knudsen in the board.

    Concit Pharma raises new capital

  • Wednesday, May 18, 2011 at 2:29PM
  • Concit Pharma raises new capital in a seed round extension. Novo Seeds, the seed fund of Novo A/S, joins as new investor



  • Concit Pharma, which was founded in 2010, develops novel medicine by reformulation and repositioning of safe and efficacious drugs to facilitate development and reduce risks. Concit Pharma is initially focused on projects within movement disorders and neuropathic pain.

  • Concit Pharma extends its seed financing by investments from new investor Novo Seed as well as existing shareholder Seed Capital. In conjunction with the investment, Bobby Soni, Principal at Novo Seeds will join the board of directors.

  • "We are happy to announce this seed round extension, and delighted to have Novo Seeds join as an investor. By having Novo Seed as a co-investor we gain significant resources and experience, which will allow us to speed up develop of our novel therapeutics", says John Bondo Hansen, CEO of Concit Pharma.

  • Bobby Soni comments: "We are happy to join Seed Capital as co-investors in Concit Pharma. Their innovative approach promises to deliver drugs that rapidly can be developed into novel treatments. We are looking forward to follow the progress of the company's lead project toward clinical testing".

  • For more information about Concit Pharma:
    John Bondo Hansen, CEO: e-mail: jbha@concitpharma.com, tel: 45 41984857.

    www.concitpharma.com